Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 102
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 8  |  Issue : 1  |  Page : 1

The UpSMART Accelerator: driving digital innovation to change the conduct of early phase cancer medicine trials


1 Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, United Kingdom
2 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
3 Research Coordination Area, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035 Barcelona, Spain
4 The Christie NHS Foundation Trust, Manchester; Division of Cancer Sciences, University of Manchester, United Kingdom
5 Cancer Research UK, London, United Kingdom
6 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; Università Statale di Milano, Milan, Italy
7 Medical Oncology – Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035 Barcelona, Spain
8 Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035 Barcelona, Spain
9 Microsoft Corporation, Berkshire, United Kingdom
10 Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester; Rekaryo Heath Ltd, West Midlands, United Kingdom
11 The Christie NHS Foundation Trust, Manchester, United Kingdom
12 Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester; Division of Cancer Sciences, University of Manchester, United Kingdom

Correspondence Address:
Butt Fouziah
digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Alderley Park, SK10 4TG
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/digm.digm_3_21

Rights and Permissions

Digitalizing clinical trials provide an opportunity to address challenges faced in the Phase I trial settings, where near real-time data capture and data interpretation are prerequisites for iterative decision-making to rapidly adapt trial designs based on emerging insights. Although digital technologies have driven significant improvements in many businesses and organizations, the adoption of digital technologies in clinical trials has been slow. In recognition of this lag, the UpSMART consortium, a 5-year funded program (2020–2024), has been established in Europe between the UK, Spain, and Italy to embrace digital technologies and drive benefits to patients. The consortium, led by the Cancer Research UK Manchester Institute Cancer Biomarker Centre, aims to 'digitalize' Experimental Cancer Medicine Centres in the UK and Early Drug Development Units in Spain and Italy by open-sourcing and sharing digital healthcare products between participating centers across the consortium. The goal is to optimize data capture and interpretation thus accelerating Phase I clinical research to ultimately benefit patients by allowing faster access to tomorrow's medicines.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed464    
    Printed22    
    Emailed0    
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal